Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel®) in patients with schizophrenia

被引:149
作者
Gefvert, O [1 ]
Bergström, M
Långström, B
Lundberg, T
Lindström, L
Yates, R
机构
[1] Vasteras Cent Hosp, Psychiat Res Unit, S-72189 Vasteras, Sweden
[2] Univ Uppsala, PET Ctr, S-75185 Uppsala, Sweden
[3] Zeneca Pharmaceut, Macclesfield, Cheshire, England
关键词
PET; pharmacokinetics; dopamine D-2 receptor; serotonin 5HT(2) receptor; atypical antipsychotic; quetiapine;
D O I
10.1007/s002130050492
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Quetiapine (Seroquel) is a novel antipsychotic with an atypical profile in animal models and a relatively short plasma half-life of 2.5-5 h. In the present study, we used PET to compare the time course of blockade of dopamine D-2 and serotonin 5HT(2) receptors of quetiapine using C-11-raclopride and C-11-N-methyl-spiperone as ligands, parallel to monitoring plasma drug concentrations. It was an open study in 11 schizophrenic men using a fixed dose of 450 mg quetiapine. Eight men completed the 29 days treatment, followed by four PET scans performed over a 26-h period after withdrawal of the compound. Quetiapine was shown to bind to dopamine D-2 receptors in striatum and 2 h (t(max)) after the last dose, 44% receptor occupancy was calculated. After 26 h it had dropped to the same level as was found in untreated healthy volunteers. Serotonin 5HT(2) receptor blockade in the frontal cortex was 72% after 2 h, which declined to 50% after 26 h. The terminal plasma half-life of quetiapine was 5.3 h, Clinically, our eight patients had good antipsychotic effect without any extrapyramidal side-effects. Out-data shows that quetiapine has a relatively low affinity for dopamine D-2 receptors, with an occupancy half-life (10 h), which was about twice as long as that for plasma. A more prolonged blockade of the serotonin 5HT(2) receptors was found in the frontal cortex, with receptor occupancy half-life of 27 h. Compared to clozapine as demonstrated in other studies, quetiapine has much the same ratio of D-2/5HT(2) occupancy. This could suggest that the combination of D-2/5HT(2) receptor blockade contributes to the antipsychotic effect and a low incidence of EPS seen with quetiapine in comparative phase three trials. Our results also confirm the clinical data that quetiapine ran be administered twice daily.
引用
收藏
页码:119 / 126
页数:8
相关论文
共 28 条
[1]   DOSE-DEPENDENT OCCUPANCY OF CENTRAL DOPAMINE-D(2) RECEPTORS BY THE NOVEL NEUROLEPTIC CP-88,059-01 - A STUDY USING POSITRON EMISSION TOMOGRAPHY AND C-11 RACLOPRIDE [J].
BENCH, CJ ;
LAMMERTSMA, AA ;
DOLAN, RJ ;
GRASBY, PM ;
WARRINGTON, SJ ;
GUNN, K ;
CUDDIGAN, M ;
TURTON, DJ ;
OSMAN, S ;
FRACKOWIAK, RSJ .
PSYCHOPHARMACOLOGY, 1993, 112 (2-3) :308-314
[2]   The time course of binding to striatal dopamine D-2 receptors by the neuroleptic ziprasidone (CP-88,059-01) determined by positron emission tomography [J].
Bench, CJ ;
Lammertsma, AA ;
Grasby, PM ;
Dolan, RJ ;
Warrington, SJ ;
Boyce, M ;
Gunn, KP ;
Brannick, LY ;
Frackowiak, RSJ .
PSYCHOPHARMACOLOGY, 1996, 124 (1-2) :141-147
[3]   5-HT2 ANTAGONIST RITANSERIN IN NEUROLEPTIC-INDUCED PARKINSONISM - A DOUBLE-BLIND COMPARISON WITH ORPHENADRINE AND PLACEBO [J].
BERSANI, G ;
GRISPINI, A ;
MARINI, S ;
PASINI, A ;
VALDUCCI, M ;
CIANI, N .
CLINICAL NEUROPHARMACOLOGY, 1990, 13 (06) :500-506
[4]  
CHIODO LA, 1983, J NEUROSCI, V3, P1607
[5]  
DELAY J, 1952, Ann Med Psychol (Paris), V110, P267
[6]  
FARDE L, 1988, ARCH GEN PSYCHIAT, V45, P71
[7]  
FARDE L, 1992, ARCH GEN PSYCHIAT, V49, P538
[8]  
FARDE L, 1989, PSYCHOPHARMACOLOGY, V99, pS98
[9]  
FLEICHHACKER WW, 1995, ACNP, P275
[10]   SEROQUEL - ELECTROPHYSIOLOGICAL PROFILE OF A POTENTIAL ATYPICAL ANTIPSYCHOTIC [J].
GOLDSTEIN, JM ;
LITWIN, LC ;
SUTTON, EB ;
MALICK, JB .
PSYCHOPHARMACOLOGY, 1993, 112 (2-3) :293-298